Tumoral @entity2282 Expression Correlates with Aggressive Histology and Prognosis in @entity1 with XXXX .

@entity1 @entity5 @entity2282 @entity3620 @entity3
BACKGROUND: Currently, @entity5 -node- @entity3 stage and histologic type are the established prognostic factors for @entity3620 , whereas no prognostic markers have been established for clinical practice. We investigated the prognostic value of @entity2282 , a metalloproteinase that can promote @entity5 through enzymatic degradation and intracellular signaling crosstalk, in @entity3620 . METHODS: @entity2282 immunostaining was performed for 176 cases of @entity3620 (epithelioid, 148; biphasic, 14; sarcomatoid, 14), and its expression was dichotomized as negative (no staining) or positive (any staining). Epithelioid @entity5 were classified as pleomorphic subtype when cytologic pleomorphism was >= 10  % of the @entity5 . Overall survival (OS) was analyzed by log-rank tests and Cox proportional hazard models. RESULTS: Tumoral @entity2282 expression was identified in 42  % of epithelioid @entity5 , 57  % of epithelioid @entity5 , 79  % of @entity5 , and 93  % of @entity5 (p  <  0.001). Positive @entity2282 expression was correlated with higher mitotic count (p  =  0.002). Overall survival for @entity1 with positive @entity2282 expression was significantly shorter than that for @entity1 with negative @entity2282 expression in all @entity1 (p  =  0.001) and in @entity1 with epithelioid @entity5 (p  =  0.04). On multivariate analysis, @entity2282 expression was an independent prognostic factor for all @entity1 (hazard ratio 1.48; p  =  0.019). CONCLUSIONS: Tumoral @entity2282 expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for @entity1 with @entity3620 .
